Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration to market Quetiapine Fumarate tablets. The tablets are the generic equivalent of AstraZeneca LP's Seroque tablets. They are indicated for the treatment of serious psychotic disorders such as schizophrenia and Bipolar Disorder and falls under the Neurological (CNS) therapeutic category. “The product has been approved out of Unit III facility in Hyderabad,” the company said in a release on Wednesday. With this, the Hyderabad-based company now has a total of 147 Abbreviated New Drug Approvals from the US regulator.
Aurobindo's scrip declined 0.61 per cent on the Bombay Stock Exchange on Wednesday to end at Rs 114.65.